TY - JOUR T1 - A lateral flow test detecting SARS-CoV-2 neutralizing antibodies JF - medRxiv DO - 10.1101/2020.11.05.20222596 SP - 2020.11.05.20222596 AU - Nan Zhang AU - Shuo Chen AU - Jin V. Wu AU - Xinhai Yang AU - Jianfu J. Wang Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/10/2020.11.05.20222596.abstract N2 - It is of critical importance for COVID-19 survivors, vaccine recipients, and public to know whether they have developed neutralizing antibodies or immunity. Here, we describe a 15 minutes lateral flow test for rapid detection of neutralizing antibodies against SARS-CoV-2. All other currently available neutralization tests require hours or days to complete and have to be performed in a well-equipped laboratory. This lateral flow test is the first of its kind and will serve as a convenient diagnostic tool in management of COVID-19 disease.Competing Interest StatementAll authors are full time employee of Novodiax Inc. N.Z., S.C. J.V.W and J.J.W. are author and inventor of a patent application that covers the NAb measurement by LFT described in this article.Funding StatementSelf supportedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by IRB with Wajeeha Mahmood, Novodiax Inc David Hagebush, Novodiax Inc Sarah Richardson, Novodiax Inc David Wages, iSpecimen IncAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll supplementary materials are in a single PDF file and are available online. https://www.novodiax.com/wp-content/uploads/2020/11/A-lateral-flow-test-detecting-SARS-CoV-2-neutralizing-antibodies-Supplementary-Information.pdf ER -